IL2 and renal cell carcinoma: The phase 3 PIVOT-09 study unexpectedly failed to improve the likelihood of response or OS with nivolumab combined with an engineered IL-2 pathway agonist (bempegaldesleukin), compared with a control TKI in patients with untreated renal cell carcinoma (RCC) [61].